A New Breakthrough In Treating Tuberculosis
Scientists have come up with a new weapon to destroy Tuberculosis. The new discovery is very promising that it might reduce the treatment duration of the patient for about an year. The new TB combination drug regimen could shrink the duration of treatment to two weeks and is capable of eradicating 99% of the bacteria. This is a good news in the field of medicine and its a great breakthrough as the TB evolves further in many forms and spread as a plague with non-resistant characteristics.
“These findings confirm the promise of novel TB regimens to be shorter, simpler, safer, and, compared with today’s MDR-TB drugs, much less expensive,” said Mel Spigelman, MD, CEO and President of TB Alliance. “The next trial to advance this regimen is already underway. We now have real momentum toward bringing to market treatments that will ultimately help save millions of lives.”
The study is named as NC-001 or New Combination-1 and is funded by the Bill & Melinda Gates Foundation, the United States Agency for International Development, UK aid, and Irish Aid. It involved the new combination therapy called PaMZ, consisting of the novel TB drug candidate, PA-824; moxifloxacin, an established antibiotic not yet approved for use in first-line TB therapy and being developed in partnership with Bayer Healthcare AG; and pyrazinamide, an existing TB drug.
“Treating drug-sensitive and drug-resistant TB with the same regimen can simplify the delivery of TB treatment worldwide,” said Andreas Diacon, MD, the trial’s principal investigator and lead author of theLancet study. “The results of this study give healthcare providers on the front lines of the TB epidemic hope for better, faster tools needed to stop this disease.”
Earlier this year a second study was also launched under the name of New Combination -002 being tested at eight sites in South Africa, Tanzania and Brazil. Most doctors consider this as a game-changer as a new potential drug for TB could be an extra-ordinary gift for the humankind.
“Because of testing drugs in combination, we have already saved several years in the research process to find new, effective regimens to treat TB,” Raviglione said. “The results look strongly promising from this early trial. If further testing holds up these results and the regimen is affordable in poor countries, it is huge progress. We could shorten drug regimens substantially for everyone, regardless of whether the form of TB is sensitive or multi-drug resistant. That would be a dramatic step forward.”
This post was first published on July 29, 2012.